Terns Pharmaceuticals, Inc.

Gossamer Bio, Inc.

Kura Oncology, Inc.

Replimune Group, Inc.

REGENXBIO Inc.

“If you had to pick a single industry that could be interesting to every hedge fund, it might be biotech,” Mergers &amp; Inquisitions founder Brian DeChesare <a href="https://mergersandinquisitions.com/biotech-hedge-funds/">wrote</a>&nbsp;in a blog post. Investments in biotechs can deliver huge gains – and huge losses – in short periods, while their stocks are often only weakly correlated with broader market trends, he noted.

Up to 840% upside: 10 smid-cap biotechs most popular with hedge funds

Revolution Medicines, Inc.

Revolution Medicines on April 13 presented breakthrough results from a study of a drug against the deadliest type of cancer. Freedom Holding co-founder Igor Klyushnev believes that this story deserves to be directed by a talented director. It is about how breakthrough clinical data is combined with high dynamics of events. And most importantly, it is a story about people who turned out to be ready for important events.

How oncology company Revolution Medicines monetized a year of operations in 48 hours 

Eli Lilly and Company

US pharmaceutical giant Eli Lilly has agreed to buy biotech company Kelonia Therapeutics in a deal worth up to $7 billion, <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell">according to</a> a press release. Lilly will pay $3.25 billion outright, with the remainder of the amount contingent on the achievement of clinical, regulatory and commercial milestones. The deal is expected to close in the second half of the year.

Eli Lilly to buy oncology drug developer. What is it paying up to $7 billion for?

Kailera Therapeutics

Shares of biotech Kailera Therapeutics Inc. are available for trading on the Freedom client trading platform. The company’s lead asset, ribupatide, is part of the multibillion-dollar race for weight-loss drugs, a market expected to exceed $150 billion over the next decade. Later on Friday, the stock will start regular-session trading on the Nasdaq under the ticker symbol <a href="https://tap.freedom24.com/to/quote/HMH.US?utm_source=stocks&amp;utm_medium=HMH.US&amp;utm_campaign=pfu17521958">KLRA</a>.

Kailera Therapeutics IPO: Shares of obesity drugmaker start trading

Alamar Biosciences

Preliminary trading in shares of biotech company Alamar Biosciences, a protein sequencing company that enables disease research and diagnosis, has begun on the Freedom client trading system. Alamar is one of several biotech companies that have continued to go public this year despite volatile market conditions, Reuters <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/kailera-alamar-launch-us-ipos-biotech-listings-gather-momentum-2026-04-13/">notes</a>. Later on April 17, Alamar Biosciences securities will appear on the Nasdaq exchange under the ticker ALMR. To participate, click on the ticker <a href="https://tap.freedom24.com/to/quote/HMH.US?utm_source=stocks&amp;utm_medium=HMH.US&amp;utm_campaign=pfu17521958">ALMR</a>.

Alamar IPO: shares of the biotech, whose mission is the early diagnosis of diseases, became available

Soleno Therapeutics, Inc.

Shares of Soleno Therapeutics, the developer of the first therapy for insatiable hunger, surged nearly 30% in early trading on Monday to $51.30 per share after Neurocrine Biosciences was reported to be nearing a more than $2.5 billion acquisition of the company, the FT <a href="https://www.ft.com/content/6642c09c-12df-4724-8ed4-a28c32b9b2b7?syn-25a6b1a6=1">wrote</a>, citing people familiar with the matter.

Extreme hunger drugmaker Soleno jumps on potential acquisition by Neurocrine

Biogen Inc.

Apellis Pharmaceuticals, Inc.

The market capitalization of Apellis Pharmaceuticals, a small-cap maker of therapies for rare kidney diseases, more than <a href="https://finance.yahoo.com/quote/APLS/">doubled</a>&nbsp;on Tuesday after it <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">said</a>&nbsp;it would be acquired at a substantial premium by pharmaceutical company Biogen.

Small-cap biotech Apellis skyrockets 135% on news of acquisition by Biogen

Merck & Co., Inc.

Pharmaceutical giant Merck, known outside of the U.S. and Canada as MSD, <a href="https://ir.ternspharma.com/news-releases/news-release-details/merck-acquire-terns-pharmaceuticals-inc-expanding-its-hematology">has agreed to acquire</a> mid-cap drug developer Terns Pharmaceuticals, which focuses on treatments for cancer and obesity. Following the news, shares of the mid cap <a href="https://finance.yahoo.com/quote/TERN/">rose</a>&nbsp;less than 6% on Wednesday. The price tag is low “considering the startlingly good data Terns put out for its chronic myeloid leukemia treatment,” William Blair analyst Andy Hsieh <a href="https://www.investors.com/news/technology/merck-terns-pharmaceuticals-takeover/?src=A00220">says</a>.

Merck to buy mid-cap biotech Terns, but William Blair thinks the price tag is low

Medtronic plc

MiniMed Group

The Company has listed on the Nasdaq under the ticker MMED

MiniMed IPO: diabetes monitoring device maker goes public

Generate Biomedicines, Inc.

The Company has listed on Nasdaq under the ticker symbol GENB

IPO Generate Biomedicines: shares of AI drug development platform become available

VolitionRx Limited

Shares of VolitionRx, a micro-cap developer of blood tests for cancer and sepsis, <a href="https://finance.yahoo.com/quote/VNRX/">jumped</a>&nbsp;nearly 26% on Tuesday after the company <a href="https://ir.volition.com/news-events/press-releases/detail/874/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution">reported</a>&nbsp;progress in several research programs and said a newly developed cancer-detection method has attracted interest from potential partners. The company also highlighted breakthrough research on detecting lymphoma in cats. Wall Street analysts <a href="https://www.marketwatch.com/investing/stock/vnrx/analystestimates?mod=mw_quote_tab">say</a>&nbsp;the stock could have nearly 790% upside.

Cancer blood test maker VolitionRX soars 25% in a day on reported commercial progress

Arcellx, Inc.

Gilead Sciences, Inc.

Shares of Arcellx, a mid-cap developer of cell therapies for blood cancers, <a href="https://finance.yahoo.com/quote/ACLX/">surged</a>&nbsp;77% on Monday to a new all-time high after the <a href="https://ir.arcellx.com/news/news-details/2026/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel/default.aspx">announcement</a>&nbsp;that its major partner, Gilead Sciences, will acquire the company at a substantial premium to the market price. For investors, the deal signals that leading pharmaceutical companies increasingly prefer full ownership of late-stage oncology assets, Noble <a href="https://www.channelchek.com/news-channel/gilead-to-acquire-arcellx-in-7-8b-bet-on-next-gen-car-t-leadership">argues</a>.

Biotechnology